StockNews.com Begins Coverage on Trevena (NASDAQ:TRVN)

StockNews.com initiated coverage on shares of Trevena (NASDAQ:TRVN) in a research note released on Sunday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Trevena Stock Performance

Trevena stock opened at $1.55 on Friday. Trevena has a fifty-two week low of $1.13 and a fifty-two week high of $19.23. The stock’s 50 day simple moving average is $3.41 and its two-hundred day simple moving average is $6.03. The stock has a market cap of $1.34 million, a price-to-earnings ratio of -0.03 and a beta of 1.08.

Trevena (NASDAQ:TRVN) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($9.25) by $9.02. The business had revenue of $0.33 million during the quarter. On average, analysts predict that Trevena will post -32.25 earnings per share for the current year.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.